nct_id,title,official_title,status,start_date,completion_date,primary_completion_date,phase,enrollment,study_type,allocation,intervention_model,primary_purpose,masking,masking_description,conditions,intervention_types,intervention_names,sponsor,sponsor_type,has_results
NCT00494013,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Comparator) in Basal Therapy for Patients With Type 2 Diabetes Mellitus,COMPLETED,2007-08,2008-09,2008-09,PHASE3,442,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Diabetes Mellitus Type 2,"DRUG, DRUG","Insulin Lispro Protamine Suspension, Detemir",Eli Lilly and Company,INDUSTRY,True
NCT02305381,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,COMPLETED,2014-12-01,2015-11-21,2015-11-21,PHASE3,397,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,True
NCT00918879,Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control,"A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise",COMPLETED,2009-05,2010-07,2010-07,PHASE3,213,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes,"DRUG, DRUG","Saxagliptin, Placebo",AstraZeneca,INDUSTRY,True
NCT02148250,PK/PD Study of U-500 Regular Insulin,Duration of Action and Peak Effect of High Dose of U-500 Regular Insulin In Severly Insulin Resistant Subjects With Type 2 Diabetes Mellitus,COMPLETED,2015-07,2017-12,2017-12,PHASE2,17,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,,"Type 2 Diabetes, Insulin Resistance, High Insulin Requirements","DRUG, DRUG","U-500 insulin, 100 syringe units, U-500 insulin, 200 syringe units",University of Minnesota,OTHER,True
NCT02737891,Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus,"A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)",COMPLETED,2016-04,2017-03,2017-01,PHASE2,60,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Tesofensine/Metoprolol, Placebo",Saniona,INDUSTRY,True
NCT04591626,A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes,"A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes",COMPLETED,2020-12-07,2022-04-28,2022-04-28,PHASE3,291,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Dulaglutide, Placebo, Insulin Glargine",Eli Lilly and Company,INDUSTRY,True
NCT00799643,Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II,Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate,COMPLETED,2008-11,,2012-09,PHASE2,638,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Salsalate, Salsalate Placebo",Joslin Diabetes Center,OTHER,True
NCT03444584,Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes,"An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 Versus Placebo in Overweight/Obese Subjects With Type 2 Diabetes Mellitus Treated With Dapagliflozin and Metformin",COMPLETED,2018-05-08,2018-12-06,2018-12-06,PHASE2,49,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Randomized, Placebo-controlled, Double-blind Study",Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","MEDI0382, Placebo, Dapaglifozin, Metformin",MedImmune LLC,INDUSTRY,True
NCT01850615,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",COMPLETED,2013-09-23,2014-11-17,2014-11-17,PHASE3,323,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","Faster-acting insulin aspart, basal insulin",Novo Nordisk A/S,INDUSTRY,True
NCT05352815,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec","A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.",COMPLETED,2022-06-01,2024-04-23,2024-03-19,PHASE3,1291,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","IcoSema, Insulin icodec",Novo Nordisk A/S,INDUSTRY,True
NCT04660643,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss,"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)",COMPLETED,2021-03-29,2023-05-18,2023-04-25,PHASE3,783,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Obesity, Overweight","DRUG, OTHER","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT00968708,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome",COMPLETED,2009-09,2013-06,2013-04,PHASE3,5380,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,"Diabetes Mellitus, Type 2, Acute Coronary Syndrome","DRUG, DRUG","Alogliptin, Placebo",Takeda,INDUSTRY,True
NCT01937598,Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D,Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin,COMPLETED,2013-08,2015-06,2014-04,PHASE3,16,INTERVENTIONAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,,Type 2 Diabetes,"DRUG, OTHER, DRUG, DRUG","Placebo, Mixed meal test, Liraglutide, Sitagliptin",Michael A. Nauck,OTHER,True
NCT02008942,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients,"Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)",COMPLETED,2014-01,2014-04,2014-04,PHASE3,57,INTERVENTIONAL,RANDOMIZED,CROSSOVER,PREVENTION,SINGLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","PL2200 Aspirin Capsules, Enteric-coated aspirin caplets",PLx Pharma,INDUSTRY,True
NCT01068665,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME),COMPLETED,2010-03,2010-11,2010-11,PHASE3,460,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,True
NCT00082381,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,COMPLETED,2003-06,2008-07,2008-07,PHASE3,551,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","Exenatide (AC2993), Insulin glargine",AstraZeneca,INDUSTRY,True
NCT01923181,"Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes","Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes",COMPLETED,2013-12-02,2014-12-11,2014-12-11,PHASE2,632,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","semaglutide, semaglutide, oral placebo",Novo Nordisk A/S,INDUSTRY,True
NCT03060577,An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol,"An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)",COMPLETED,2017-04-27,2021-12-17,2021-12-17,PHASE2,382,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia","DRUG, DRUG","Inclisiran, Evolocumab",Novartis Pharmaceuticals,INDUSTRY,True
NCT00749190,BI 10773 add-on to Metformin in Patients With Type 2 Diabetes,"A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy",COMPLETED,2008-08,,2009-10,PHASE2,495,INTERVENTIONAL,,PARALLEL,TREATMENT,,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","BI 10773, placebo, sitagliptin",Boehringer Ingelheim,INDUSTRY,True
NCT01191320,Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus,A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment,COMPLETED,2010-10,2011-12,2011-12,PHASE2,102,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,"Type 2 Diabetes Mellitus, Secondary Hypogonadism","DRUG, DRUG","Placebo, Androxal",Repros Therapeutics Inc.,INDUSTRY,True
NCT03091920,"Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension","A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension",COMPLETED,2017-02-28,2017-08-03,2017-08-03,PHASE2,26,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Double-Blind,"Diabetes Mellitus, Type 2, Hypertension","DRUG, DRUG","IW-1973, Placebo",Cyclerion Therapeutics,INDUSTRY,True
NCT00395746,Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes,COMPLETED,2006-10,2008-05,2007-10,PHASE3,264,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","sulfonylurea, liraglutide, liraglutide",Novo Nordisk A/S,INDUSTRY,True
NCT01177384,Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130),"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Acarbose Monotherapy",COMPLETED,2011-01-25,2013-03-25,2013-03-25,PHASE3,380,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Sitagliptin phosphate, Comparator: Placebo, Acarbose, Glimepiride",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT01475461,Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes,"A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin",COMPLETED,2011-11,2013-01,2013-01,PHASE2,345,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg",Pfizer,INDUSTRY,True
NCT02004886,"A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)","A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2006-08-11,2007-02-07,2007-02-07,PHASE2,74,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","MK-0893, Metformin, Placebo, Placebo",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT00707993,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes",COMPLETED,2008-06,2010-08,2010-08,PHASE3,441,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Diabetes Mellitus,"DRUG, DRUG","Alogliptin, Glipizide",Takeda,INDUSTRY,True
NCT02453555,Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus,"A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.",COMPLETED,2015-05-14,2017-03-27,2016-08-26,PHASE3,275,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Linagliptin, Empagliflozin placebo + linagliptin placebo low dose, Empagliflozin + linagliptin low dose, Linagliptin placebo, Empagliflozin + linagliptin high dose, Empa + lina highdose placebo",Boehringer Ingelheim,INDUSTRY,True
NCT01340768,Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262),"An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting",COMPLETED,2010-06-22,2011-09-21,2011-09-21,PHASE3,870,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin, Sulfonylurea, Metformin",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT03259789,Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone",COMPLETED,2017-11-28,2019-01-23,2019-01-23,PHASE3,351,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Type2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Bexagliflozin tablets, 20 mg, Bexagliflozin tablets, placebo, Bexagliflozin tablets, 20 mg",Theracos,INDUSTRY,True
NCT00130208,Effect of Sulodexide in Early Diabetic Nephropathy,The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria,COMPLETED,2005-08,2008-02,2008-01,PHASE3,1056,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Diabetic Nephropathy,"DRUG, DRUG","Sulodexide, Placebo",Keryx Biopharmaceuticals,INDUSTRY,True
NCT00601250,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,"A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (One Dose, e.g. 5 mg), Administered Orally Once Daily Over 24 Weeks, With an Open Label Extension to 80 Weeks (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy",COMPLETED,2008-01,,2009-05,PHASE3,701,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","linagliptin, linagliptin",Boehringer Ingelheim,INDUSTRY,True
NCT04867785,A Study of LY3437943 in Participants With Type 2 Diabetes,A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes,COMPLETED,2021-05-13,2022-10-27,2022-07-08,PHASE2,281,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes,"DRUG, DRUG, DRUG","LY3437943, Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT01011868,Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes,"A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control",COMPLETED,2009-11,,2012-05,PHASE2,494,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","BI 10773 placebo, BI 10773 low dose, BI 10773 high dose, BI 10773 placebo",Boehringer Ingelheim,INDUSTRY,True
NCT00434954,Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes,Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment,COMPLETED,2007-02,2009-06,2009-06,PHASE3,494,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","exenatide twice daily (BID), premixed insulin aspart twice daily (BID)",AstraZeneca,INDUSTRY,True
NCT05258630,Diabetes Homeless Medication Support,Diabetes Homeless Medication Support Randomized Pilot Treatment Development Trial (D-Homes),COMPLETED,2022-02-23,2023-07-12,2023-04-27,PHASE2,38,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Study staff completing post-treatment assessments will be blinded to study condition allocation.,"Diabetes Mellitus, Type 2, Housing Problems, Psychological Distress","BEHAVIORAL, BEHAVIORAL","Diabetes Homeless Medication Support (D-Homes), Enhanced usual care",Hennepin Healthcare Research Institute,OTHER,True
NCT00727857,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,"A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes",COMPLETED,2007-06,2008-08,2008-08,PHASE3,600,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Diabetes Mellitus,"DRUG, DRUG, DRUG","Pioglitazone and metformin, Pioglitazone, Metformin",Takeda,INDUSTRY,True
NCT01336738,Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus,"A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin",COMPLETED,2011-06,2012-03,2012-03,PHASE2,266,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg",Pfizer,INDUSTRY,True
NCT04093752,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo),"A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea",COMPLETED,2019-12-09,2021-11-24,2021-11-01,PHASE3,917,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes,"DRUG, DRUG","Tirzepatide, Insulin Glargine",Eli Lilly and Company,INDUSTRY,True
NCT02692716,A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes,A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes,COMPLETED,2017-01-17,2018-09-25,2018-09-25,PHASE3,3183,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,True
NCT01289119,Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes",COMPLETED,2010-12,2011-12,2011-12,PHASE3,506,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Alogliptin, Placebo to alogliptin, Metformin, Pioglitazone",Takeda,INDUSTRY,True
NCT02924064,Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus,,COMPLETED,2016-09,,2018-09-25,PHASE3,247,INTERVENTIONAL,,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Teneligliptin 20mg, Placebo, Metformin ≥ 1000 mg",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True
NCT01798706,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen",COMPLETED,2013-06,2015-02,2015-02,PHASE3,350,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes,"DRUG, DRUG, DRUG","Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy",Sanofi,INDUSTRY,True
NCT00330733,Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk,Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk,COMPLETED,2007-01,2010-09,2010-08,PHASE2,71,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,,"Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus","DRUG, DRUG","Salsalate, Placebo",VA Office of Research and Development,FED,True
NCT01991197,Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.,Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.,COMPLETED,2014-04,2016-01,2016-01,PHASE2,20,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,,"Psoriasis, Type 2 Diabetes Mellitus","DRUG, DRUG, DRUG, DRUG","Sitagliptin, Gliclazide, Sitagliptin matched placebo, Gliclazide matched placebo capsule",University College Dublin,OTHER,True
NCT01629862,Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea,Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea.,COMPLETED,2012-04,2017-02,2017-02,PHASE2,53,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Sleep Apnea, Obstructive, Diabetes Mellitus","DEVICE, DEVICE","Continuous positive airway pressure, Sham continuous positive airway pressure",Sanjay R Patel,OTHER,True
NCT01059825,"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin",COMPLETED,2010-02-24,2011-01-20,2011-01-20,PHASE2,375,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo to Ertugliflozin, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, Sitagliptin 100 mg, Placebo to Sitagliptin, Metformin",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT04605991,A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range),A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring,COMPLETED,2020-11-04,2022-02-04,2022-02-04,PHASE3,187,INTERVENTIONAL,NA,SINGLE_GROUP,TREATMENT,NONE,,Type 2 Diabetes,"DRUG, DRUG","LY900014, Insulin Glargine",Eli Lilly and Company,INDUSTRY,True
NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4),COMPLETED,2018-11-20,2021-04-22,2021-01-22,PHASE3,2002,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Tirzepatide, Insulin Glargine",Eli Lilly and Company,INDUSTRY,True
NCT01357889,Pharmacokinetics/Pharmacodynamics of Albiglutide,A Multidose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide,COMPLETED,2011-07,2012-10,2012-10,PHASE2,283,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","BIOLOGICAL, BIOLOGICAL","albiglutide (GSK716155), albiglutide (GSK716155)",GlaxoSmithKline,INDUSTRY,True
NCT01075282,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2),"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride",COMPLETED,2010-02,2012-11,2012-05,PHASE3,810,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Insulin Glargine, LY2189265, Metformin, Glimepiride",Eli Lilly and Company,INDUSTRY,True
NCT02532855,A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838),"A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea",COMPLETED,2015-10-20,2017-10-10,2017-10-10,PHASE3,614,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Sitagliptin, Dapagliflozin, Metformin, Matching placebo to sitagliptin, Matching placebo to dapagliflozin, Sulfonylurea",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT00545584,Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078),"Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy",COMPLETED,2007-04-01,2009-11-19,2009-11-19,PHASE3,1512,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, BEHAVIORAL, BEHAVIORAL","sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT01394952,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND),COMPLETED,2011-07-22,2018-08-21,2018-08-21,PHASE3,9901,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Cardiovascular Disease, Diabetes Mellitus, Type 2","DRUG, DRUG","Dulaglutide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT01554618,Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes,"A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes",COMPLETED,2011-12-02,2021-05-05,2020-05-06,PHASE3,84,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Children and Adolescent With Type 2 Diabetes,"DRUG, DRUG","Exenatide Once Weekly, Placebo",AstraZeneca,INDUSTRY,True
NCT00348374,Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes,"A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Trial Assessing The Efficacy Of Exubera Vs. Lispro Introduced Into A Lantus Based Regimen In Suboptimally Controlled Patients With Type 2 Diabetes Mellitus",COMPLETED,2006-06,2008-08,2008-08,PHASE3,191,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Diabetes Mellitus,"DRUG, DRUG","Insulin Lispro, Exubera",Pfizer,INDUSTRY,True
NCT01607450,Modulation of Human Myocardial Metabolism by GLP-1 Dose Response,Modulation of Human Myocardial Metabolism by GLP-1 Dose Response,COMPLETED,2010-05,2012-12,2012-12,PHASE2,33,INTERVENTIONAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,,"Type 2 Diabetes Mellitus, Healthy","DRUG, DRUG, DRUG, DRUG","GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline",Indiana University,OTHER,True
NCT01841697,Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026),"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",COMPLETED,2013-06-13,2014-11-17,2014-11-17,PHASE3,642,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Omarigliptin, Sitagliptin, Placebo to omarigliptin, Placebo to Sitagliptin, Open-label Metformin, Open-label Glimepiride",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT02227875,Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2),"An Open-label, Randomized, Multi-center, Parallel Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients",COMPLETED,2014-08,2015-12,2015-12,PHASE3,560,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes,"DRUG, DRUG","Mylan's insulin glargine, Lantus®",Mylan Inc.,INDUSTRY,True
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease",COMPLETED,2012-07,2016-12,2016-06,PHASE3,577,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Dulaglutide dose was blinded to participant, care provider, investigator and outcomes assessor.","Type 2 Diabetes, Chronic Kidney Disease","DRUG, DRUG, DRUG","Dulaglutide, Insulin glargine, Insulin lispro",Eli Lilly and Company,INDUSTRY,True
NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,COMPLETED,2014-08-04,2015-09-03,2015-09-03,PHASE3,1089,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, insulin glargine",Novo Nordisk A/S,INDUSTRY,True
NCT04657016,A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program,"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)",COMPLETED,2021-03-29,2023-05-12,2023-04-20,PHASE3,579,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Obesity, Overweight","DRUG, OTHER","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT02397447,"Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion","Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment",COMPLETED,2013-03,2015-11,2015-11,PHASE2,24,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Diabetes Mellitus Type 2,"DRUG, DRUG","Momordica charantia, Placebo",University of Guadalajara,OTHER,True
NCT03738865,G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes,"G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety",COMPLETED,2018-09-27,2019-04-02,2019-03-29,PHASE3,132,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,,"Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia","DRUG, DRUG","G-Pen, Novo Glucagon",Xeris Pharmaceuticals,INDUSTRY,True
NCT00420511,Beta-Cell Function and Sitagliptin Trial (BEST),A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes,COMPLETED,2007-01,2009-09,2009-09,PHASE2,21,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Sitagliptin, Placebo, metformin","Samuel Lunenfeld Research Institute, Mount Sinai Hospital",OTHER,True
NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,"Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)",COMPLETED,2019-12-04,2024-07-06,2022-04-01,PHASE3,2539,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Overweight, Obesity","DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT02973321,A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus,"A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2016-12-02,2017-12-27,2017-12-27,PHASE2,296,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","SAR425899, Placebo, Liraglutide, Metformin",Sanofi,INDUSTRY,True
NCT02068443,Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy,"A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients",COMPLETED,2014-02,2015-02,2015-02,PHASE3,374,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","Alogliptin, Metformin hydrochloride, Metformin hydrochloride Placebo",Takeda,INDUSTRY,True
NCT00976391,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2009-09,2012-05,2011-10,PHASE3,586,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin",GlaxoSmithKline,INDUSTRY,True
NCT03311724,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,"A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus",COMPLETED,2017-10-19,2018-04-24,2018-04-24,PHASE2,111,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes,"DRUG, DRUG","Tirzepatide, Placebo",Eli Lilly and Company,INDUSTRY,True
NCT00379769,RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes,"A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia",COMPLETED,2001-04,2008-12,2008-12,PHASE3,4447,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Rosiglitazone, Sulfonylurea, Metformin",GlaxoSmithKline,INDUSTRY,True
NCT02279407,A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients,"A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II",COMPLETED,2015-01,2015-12,2015-12,PHASE2,223,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin),"DRUG, DRUG, DRUG, DRUG","placebo, Omega-3 carboxylic acids, Dapagliflozin, Placebo",AstraZeneca,INDUSTRY,True
NCT01558271,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus,COMPLETED,2012-03,2014-05,2013-10,PHASE3,492,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","LY2189265, Placebo, Liraglutide",Eli Lilly and Company,INDUSTRY,True
NCT00095056,An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED),Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency,COMPLETED,2004-10,2006-07,2006-07,PHASE3,91,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2, Chronic Renal Insufficiency","DRUG, DRUG, DRUG, DRUG","sitagliptin, Placebo to Sitagliptin, glipizide, Placebo to glipizide",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT02647320,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,"A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin",COMPLETED,2016-01,2017-01-31,2017-01-31,PHASE2,298,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Sitagliptin 100 mg, DS-8500a 25mg, Placebo Tablet, Placebo Capsule",Daiichi Sankyo,INDUSTRY,True
NCT04848480,"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","Efficacy and Safety of Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. A 26-week, Randomised, Multicentre, Open-label, Active-controlled, Parallel Group, Two Armed, Treat-to-target Trial Investigating the Effect on Glycaemic Control and Safety of Treatment With Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec, Both in Combination With Insulin Aspart in Adults With Type 1 Diabetes, With a 26-week Extension Investigating Long Term Safety",COMPLETED,2021-04-30,2022-12-02,2022-04-28,PHASE3,582,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 1","DRUG, DRUG, DRUG","insulin icodec, insulin degludec, insulin aspart",Novo Nordisk A/S,INDUSTRY,True
NCT01792518,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)",COMPLETED,2013-02,2015-12,2015-11,PHASE3,360,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","Placebo, Linagliptin 5mg",Boehringer Ingelheim,INDUSTRY,True
NCT01682759,A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016),"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",COMPLETED,2012-09-10,2015-01-26,2015-01-26,PHASE3,751,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Omarigliptin, Placebo to Omarigliptin, Glimepiride, Glimepiride Placebo, Metformin, Insulin Glargine",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT03459079,Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease,"Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease",COMPLETED,2018-08-14,2023-06-01,2023-04-18,PHASE2,128,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"double-blind, placebo-controlled trial.","Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)","DRUG, OTHER","Lanifibranor, Placebo",University of Florida,OTHER,True
NCT02906579,"A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension","An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension",COMPLETED,2016-09,2017-03-17,2017-03-17,PHASE2,11,INTERVENTIONAL,NA,SINGLE_GROUP,TREATMENT,NONE,,"Diabetes Mellitus, Type 2, Hypertension","DRUG, DRUG","Matching Placebo, IW-1973",Cyclerion Therapeutics,INDUSTRY,True
NCT00485758,Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069),"A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes",COMPLETED,2007-07,2008-08,2008-08,PHASE3,796,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Diabetes Mellitus Type 2,"DRUG, DRUG","ER niacin/laropiprant, Comparator : placebo (unspecified)",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT00855166,Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes,"A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone",COMPLETED,2009-02,2011-12,2010-06,PHASE3,182,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Dapagliflozin, Metformin, Sitagliptin, Placebo",AstraZeneca,INDUSTRY,True
NCT00377676,Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo",COMPLETED,2004-07,2007-01,2007-01,PHASE3,3095,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Cycloset, Usual Diabetes Therapy plus placebo",VeroScience,INDUSTRY,True
NCT00663260,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control",COMPLETED,2008-06,2011-06,2009-12,PHASE2,631,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Dapagliflozin, Dapagliflozin, Placebo",AstraZeneca,INDUSTRY,True
NCT01517373,Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin,"A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin",COMPLETED,2012-02,2013-01,2013-01,PHASE2,304,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride",Pfizer,INDUSTRY,True
NCT02752880,YH1 in Poorly Controlled Type 2 Diabetes,"The Efficacy and Safety of Concentrated Herbal Extract Granules, YH1, as an Add-On Medication in Poorly Controlled Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial",COMPLETED,2016-06,2018-02,2018-02,PHASE2,46,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Type 2 Diabetes,"DRUG, DRUG","YH1 group, placebo group",Chang Gung Memorial Hospital,OTHER,True
NCT00839527,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,"A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2009-02,2013-04,2012-01,PHASE3,685,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG","placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone",GlaxoSmithKline,INDUSTRY,True
NCT01381900,"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",COMPLETED,2011-08,2012-11,2012-11,PHASE3,678,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Canagliflozin 100mg, Canagliflozin 300mg, Metformin, Sulphonylurea","Janssen Research & Development, LLC",INDUSTRY,True
NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of Dapagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycemic Control.",COMPLETED,2015-06-15,2017-11-07,2017-11-07,PHASE3,321,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin",AstraZeneca,INDUSTRY,True
NCT00701090,A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED),"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",COMPLETED,2008-05,2009-10,2009-10,PHASE3,1035,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG, DRUG","sitagliptin, Comparator: glimepiride, open-label metformin",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT00532935,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of the MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus",COMPLETED,2008-01-26,2009-10-23,2009-10-23,PHASE3,517,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT00982644,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,"NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)",COMPLETED,2009-09,2010-12,2010-12,PHASE3,1030,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec, insulin glargine",Novo Nordisk A/S,INDUSTRY,True
NCT01387737,Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus,"An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2011-05,2012-12,2012-11,PHASE3,1299,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","TA-7284-Low, TA-7284-High",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True
NCT00972283,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,"NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)",COMPLETED,2009-09-01,2010-10-28,2010-10-28,PHASE3,1006,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin degludec, insulin glargine, insulin aspart",Novo Nordisk A/S,INDUSTRY,True
NCT03550378,A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment",COMPLETED,2018-06-29,2019-02-04,2019-02-04,PHASE2,41,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Type II Diabetes Mellitus, Renal Insufficiency","DRUG, DRUG","MEDI0382, Placebo",MedImmune LLC,INDUSTRY,True
NCT00937326,Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects,"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",COMPLETED,2009-08-19,2010-09-18,2010-09-18,PHASE2,227,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG","SRT2104, Placebo","Sirtris, a GSK Company",INDUSTRY,True
NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors,COMPLETED,2017-03-03,2018-05-08,2018-05-04,PHASE3,303,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","liraglutide, placebo",Novo Nordisk A/S,INDUSTRY,True
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Actos Now for Prevention of Diabetes (ACT NOW),COMPLETED,2004-01,2010-04,2010-04,PHASE3,602,INTERVENTIONAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,,"Impaired Glucose Tolerance, Type 2 Diabetes","DRUG, DRUG","Pioglitazone, Placebo",The University of Texas Health Science Center at San Antonio,OTHER,True
NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone",COMPLETED,2016-02-26,2017-07-15,2017-07-15,PHASE3,905,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","DRUG, DRUG, DRUG, DRUG","Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin",AstraZeneca,INDUSTRY,True
NCT01128894,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2010-05,2011-09,2011-09,PHASE3,841,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes Mellitus, Type 2","BIOLOGICAL, DRUG","albiglutide, liraglutide",GlaxoSmithKline,INDUSTRY,True
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",COMPLETED,2008-06,2009-08,2009-08,PHASE3,994,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes,"DRUG, DRUG","Dapagliflozin, Metformin XR",AstraZeneca,INDUSTRY,True
NCT00962065,Study of LX4211 in Subjects With Type 2 Diabetes Mellitus,"A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2009-08,,2009-12,PHASE2,36,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG","LX4211 Low Dose, LX4211 High Dose, Placebo",Lexicon Pharmaceuticals,INDUSTRY,True
NCT02906930,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.,COMPLETED,2016-09-20,2017-12-08,2017-10-30,PHASE3,703,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","semaglutide, placebo",Novo Nordisk A/S,INDUSTRY,True
NCT01081834,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",COMPLETED,2010-03,2012-03,2011-08,PHASE3,678,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","Canagliflozin, Placebo, Sitagliptin","Janssen Research & Development, LLC",INDUSTRY,True
NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,COMPLETED,2017-03-15,2018-11-16,2018-10-16,PHASE3,788,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG","Semaglutide, Canagliflozin, Placebo (canagliflozin), Placebo (semaglutide)",Novo Nordisk A/S,INDUSTRY,True
NCT01880736,A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes,A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes,COMPLETED,2013-06,2014-04,2014-04,PHASE3,458,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG","insulin degludec, insulin degludec, insulin degludec",Novo Nordisk A/S,INDUSTRY,True
NCT05662332,A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1),"A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes",COMPLETED,2023-01-14,2024-07-19,2024-07-19,PHASE3,795,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sponsor will be blinded throughout the study.,"Type 2 Diabetes, T2D","DRUG, DRUG","Insulin Efsitora Alfa, Insulin Glargine",Eli Lilly and Company,INDUSTRY,True
NCT01649297,A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy,"A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control",COMPLETED,2012-10,2013-12,2013-12,PHASE2,983,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Type 2","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Placebo, Placebo, Placebo, Placebo, Placebo, empagliflozin (low dose qd), Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Empagliflozin (high dose qd), empagliflozin (high dose bid), Placebo, empagliflozin (low dose bid)",Boehringer Ingelheim,INDUSTRY,True
NCT02151461,Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients,"A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes",COMPLETED,2014-07,2016-01,2015-08,PHASE2,96,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG, DRUG, DRUG","Low Metformin, Metformin, Mid Metformin, High Metformin",NuSirt Biopharma,INDUSTRY,True
NCT00974090,Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes,A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus,COMPLETED,2009-09,2011-03,2011-03,PHASE3,194,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Type 2 Diabetes Mellitus,"DRUG, DRUG","Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea), Teneli / Teneli + SU",Mitsubishi Tanabe Pharma Corporation,INDUSTRY,True
NCT00577824,Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s),Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled,COMPLETED,2008-01,2008-11,2008-11,PHASE3,181,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,Type 2 Diabetes,"DRUG, DRUG, DRUG","exenatide, exenatide, placebo",AstraZeneca,INDUSTRY,True
NCT00773279,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen® in Subjects With Type 1 or Type 2 Diabetes",COMPLETED,2008-09,2009-06,2009-06,PHASE3,242,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems","DEVICE, DEVICE","FlexTouch®, FlexPen®",Novo Nordisk A/S,INDUSTRY,True
NCT04595370,"Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease","A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease",COMPLETED,2021-01-26,2023-09-22,2023-09-22,PHASE2,153,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,"Heart Failure, Chronic Kidney Disease","DRUG, DRUG","AZD9977, Dapagliflozin",AstraZeneca,INDUSTRY,True
NCT04556760,"Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes","A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes",COMPLETED,2020-11-26,2021-06-09,2021-06-09,PHASE2,46,INTERVENTIONAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Both participants and investigators will be blinded. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study. In order to maintain this blind, a third party will be responsible for the reconstitution and dispensation of all study interventions.","Diabetes Mellitus, Type 2","DRUG, DRUG, OTHER","AZD9567, Prednisolone, Placebo",AstraZeneca,INDUSTRY,True
NCT00758069,Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045),Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects,COMPLETED,2005-07-03,2006-02-13,2006-02-13,PHASE2,80,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,,"Diabetes Mellitus, Non-Insulin-Dependent","DRUG, DRUG, DRUG","sitagliptin phosphate, Comparator: Placebo, Comparator: Sitagliptin",Merck Sharp & Dohme LLC,INDUSTRY,True
NCT03371355,"Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)",COMPLETED,2017-12-21,2020-02-24,2019-11-21,PHASE2,105,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,"NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic","DRUG, DRUG, DRUG, DRUG","Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg",Akcea Therapeutics,INDUSTRY,True
NCT01045447,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL)",COMPLETED,2010-01,2010-10,2010-10,PHASE3,465,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,,"Diabetes, Diabetes Mellitus, Type 2","DRUG, DRUG","insulin degludec/insulin aspart, insulin glargine",Novo Nordisk A/S,INDUSTRY,True
